A growing buzz about potential safety issues has raised a cloud of doubt about Merck’s osteoporosis drug odanacatib, which is likely to linger now that the pharma giant has released Phase III results and laid out plans for a delayed FDA filing.

…read more

Source: UPDATED: Safety concerns cloud odanacatib PhIII as Merck steps back from FDA filing